For selected applicants, the agency plans to cut review times down to one to two months and provide "tumor board-style" ...

In the growing rare disease precision medicine market, drug companies must avoid funding genetic testing that the Justice ...

The agency maintains that the beta-amyloid-targeting drugs show too limited benefit to justify their cost to the National Health Service.

NEW YORK – Archeus Technologies on Friday said the US Food and Drug Administration cleared its investigational new drug application (IND) for the theranostic radiopharmaceutical agent ART-101 in ...

Studies doing genome-wide testing can easily ID patients with naturally low neutrophil counts, but nobody's looking at it, ...

NEW YORK – Singapore's Ministry of Health announced this week it will launch a genetic testing program to improve diagnosis of familial hypercholesterolemia (FH) as part of a broader national focus on ...

Trump administration health officials assured drugmakers and researchers at a roundtable hosted by the FDA that they want to ...

Medical ethicists are bringing attention to an early chapter of precision medicine history, an often overlooked aspect of an ...

The adaptive, biomarker-directed trial allows researchers to enrich for best responders and open new sub-studies for non-responders based on emerging data.

The funds will support the firm's lead programs, ABS-1230 for KCNT1-related epilepsy and ABS-0871 for TRPV4-positive Charcot-Marie-Tooth disease type 2C.